Table S1: OX1222 Phase I Study Patients Treated with OXi4503 in combination with Cytarabine (OXA) according to dose cohorts of OXi4503.
Note: When the same event was reported twice for the same patient, it was only counted once, and the highest grade was captured. Note: When the same event was reported twice for the same patient, it was only counted once, and the highest grade was captured. Table S7 . Incidence of laboratory abnormalities* CTCAE Grade 3-4 by MedDRA PT regardless of any relationship with the study drug OXi4503.
Note: When the same event was reported twice for the same patient, it was only counted once, and the highest grade was captured. *This table includes lab abnormalities reported as adverse events. .  Table S10 . All study drug-related Grade 3-4 adverse events* reported in Study OX1222. There were no incidences of drug-related Grade 5 adverse events.
